Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 21Lymphoma 10Lymphoma, Mantle-Cell 4Waldenstrom Macroglobulinemia 2Recurrence 2Mesothelioma, Malignant 2Lymphoma, Follicular 2Stomach Neoplasms 1Sezary Syndrome 1Rectal Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Immunoglobulin Light-chain Amyloidosis 1Hematologic Neoplasms 1Disease 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 3carfilzomib 2Dexamethasone 2deltacortene 1daratumumab 1Melphalan 1Magnetic Resonance Spectroscopy 1Calcium Dobesilate 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Disease × Bortezomib × Clear all
NCT01190787 2024-01-23

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

European Myeloma Network B.V.

Phase 2 Completed
150 enrolled
Plasma cell

Disease, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡